185 related articles for article (PubMed ID: 12788183)
1. Radiation exposure to family and household members after prostate brachytherapy.
Michalski J; Mutic S; Eichling J; Ahmed SN
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):764-8. PubMed ID: 12788183
[TBL] [Abstract][Full Text] [Related]
2. Radiation exposure after permanent prostate brachytherapy.
Cattani F; Vavassori A; Polo A; Rondi E; Cambria R; Orecchia R; Tosi G
Radiother Oncol; 2006 Apr; 79(1):65-9. PubMed ID: 16564593
[TBL] [Abstract][Full Text] [Related]
3. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98.
International Commission on Radiological Protection
Ann ICRP; 2005; 35(3):iii-vi, 3-50. PubMed ID: 16330284
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of direct radiation exposure measurements for family members living with patients with prostate (125)I seed implantation: Evidence of radiation safety.
Hanada T; Yorozu A; Shinya Y; Kuroiwa N; Ohashi T; Saito S; Shigematsu N
Brachytherapy; 2016; 15(4):412-419. PubMed ID: 27180131
[TBL] [Abstract][Full Text] [Related]
5. A radiation badge survey for family members living with patients treated with a (103)Pd permanent breast seed implant.
Keller BM; Pignol JP; Rakovitch E; Sankreacha R; O'Brien P
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):267-71. PubMed ID: 17967512
[TBL] [Abstract][Full Text] [Related]
6. A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations.
Keller B; Sankreacha R; Rakovitch E; O'brien P; Pignol JP
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):358-65. PubMed ID: 15890575
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer.
Penfold SN; Marcu L; Lawson JM; Asp J
J Radiol Prot; 2012 Sep; 32(3):339-47. PubMed ID: 22854245
[TBL] [Abstract][Full Text] [Related]
8. Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.
Nasser NJ; Cohen GN; Dauer LT; Zelefsky MJ
Brachytherapy; 2016; 15(4):420-425. PubMed ID: 27180125
[TBL] [Abstract][Full Text] [Related]
9. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
10. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction.
Merrick GS; Wallner K; Butler WM; Galbreath RW; Lief JH; Benson ML
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):597-604. PubMed ID: 11395225
[TBL] [Abstract][Full Text] [Related]
11. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
[TBL] [Abstract][Full Text] [Related]
12. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma.
Grigsby PW; Siegel BA; Baker S; Eichling JO
JAMA; 2000 May; 283(17):2272-4. PubMed ID: 10807387
[TBL] [Abstract][Full Text] [Related]
13. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism.
Barrington SF; O'Doherty MJ; Kettle AG; Thomson WH; Mountford PJ; Burrell DN; Farrell RJ; Batchelor S; Seed P; Harding LK
Eur J Nucl Med; 1999 Jul; 26(7):686-92. PubMed ID: 10398815
[TBL] [Abstract][Full Text] [Related]
14. Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy.
Dauer LT; Zelefsky MJ; Horan C; Yamada Y; St Germain J
Brachytherapy; 2004; 3(1):1-6. PubMed ID: 15110306
[TBL] [Abstract][Full Text] [Related]
15. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
16. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Donzella JG
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1069-74. PubMed ID: 11072164
[TBL] [Abstract][Full Text] [Related]
17. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract][Full Text] [Related]
18. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
19. Radiation protection of persons living close to patients with radioactive implants.
Kaulich TW; Bamberg M
Strahlenther Onkol; 2010 Feb; 186(2):107-112. PubMed ID: 20127228
[TBL] [Abstract][Full Text] [Related]
20. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
